Alnylam Pharmaceuticals and The Medicines Company Announce that New ALN-PCSsc Results from Late-Breaking Presentation at American Heart Association Meeting Confirm Potential for Bi-Annual Hypercholest

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to Alnylam Pharmaceuticals and The Medicines Company Announce that New ALN-PCSsc Results from Late-Breaking Presentation at American Heart Association Meeting Confirm Potential for Bi-Annual Hypercholest

Alnylam's (ALNY) Strong ALN-PCSsc Data at AHA Conference, FBR Capital Notes

November 12, 2015 7:43 AM EST

Yesterday, November 11, Alnylam Pharmaceuticals (NASDAQ: ALNY) and The Medicines Company (NASDAQ: MDCO) reported ALN-PCSsc Phase I data during a late-breaker session at the American Heart Association (AHA) meeting held in Orlando.

The additional data in healthy volunteers... More

Medicines Co. (MDCO), Alnylam' (ALNY) ALN-PCSsc Data Affirm Potential bi-Annual Dose Regimen - Chardan Capital

November 11, 2015 12:35 PM EST

Chardan Capital affirms Medicines Company (Nasdaq: MDCO) with a Buy rating and $50 price target after the company and Alnylam (Nasdaq: ALNY)... More

Alnylam Pharma (ALNY), Medicines Co. (MDCO) Announce Positive Data from Ongoing ALN-PCSsc Phase 1

November 11, 2015 10:47 AM EST

Alnylam Pharma (NASDAQ: ALNY) and The Medicines Company (Nasdaq: MDCO) reported positive results from their ongoing Phase 1 clinical trial with ALN-PCSsc in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2015.

ALN-PCSsc is an investigational RNAi therapeutic... More